Aflibercept biosimilars for retinal disease
A meta-analysis compared aflibercept biosimilars with reference aflibercept in neovascular AMD and diabetic macular oedema.
doi: 10.1016/j.survophthal.2025.11.007Aflibercept
Aflibercept 8 mg for DME: 96-week PHOTON results
PHOTON compared 8 mg aflibercept at extended intervals with standard 2 mg dosing every eight weeks.
doi: 10.1016/j.ophtha.2025.10.028